Satralizumab
Satralizumab is a humanized monoclonal antibody that is used for the treatment of neuromyelitis optica spectrum disorders (NMOSD). It is marketed under the brand name Enspryng and is developed by Roche.
Mechanism of Action[edit]
Satralizumab works by binding to the interleukin-6 (IL-6) receptor and inhibiting the signal transduction of IL-6, a cytokine that plays a key role in the inflammatory process in NMOSD.
Clinical Trials[edit]
In clinical trials, Satralizumab has shown to reduce the risk of NMOSD relapse. Side effects were similar to those seen in the general population, with the most common being nasopharyngitis and headache.
Approval[edit]
Satralizumab was approved for medical use in the United States in August 2020. In the European Union, it was granted a conditional marketing authorization in April 2021.
See Also[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
